Alexander Laemmle

Dr. Alexander Laemmle

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2021 in Hepatology
Verified
Journal Article
Open access
PDF file
ALAlexander Laemmle
Alexander Laemmle
MPMartin Poms
Martin Poms
BHBernadette Hsu
Bernadette Hsu
MBMariia Borsuk
Mariia Borsuk
VRVéronique Rüfenacht
Véronique Rüfenacht
HWHolger Willenbring
Holger Willenbring
Background and Aims: Patient‐derived human‐induced pluripotent stem cells (hiPSCs) differentiated into hepatocytes (hiPSC‐Heps) have facilitated the study of rare genetic liver diseases. Here, we aimed to establish an in vitro liver disease model of the urea cycle disorder ornithine transcarbamylase deficiency (OTCD) using patient‐derived hiPSC‐Heps. Approach and Results: Before modeling OTCD, we addressed the question of why hiPSC‐Heps generally secrete less urea than adult primary human hepatocytes (PHHs). Because hiPSC‐Heps are not completely differentiated and maintain some characteristics of fetal PHHs, we compared gene‐expression levels in human fetal and adult liver tissue to identify genes responsible for reduced urea secretion in hiPSC‐Heps. We found lack of aquaporin 9 (AQP9) expression in fetal liver tissue as well as in hiPSC‐Heps, and showed that forced expression of AQP9 in hiPSC‐Heps restores urea secretion and normalizes the response to ammonia challenge by increasing ureagenesis. Furthermore, we proved functional ureagenesis by challenging AQP9‐expressing hiPSC‐Heps with ammonium chloride labeled with the stable isotope [15N] (15NH4Cl) and by assessing enrichment of [15N]‐labeled urea. Finally, using hiPSC‐Heps derived from patients with OTCD, we generated a liver disease model that recapitulates the hepatic manifestation of the human disease. Restoring OTC expression—together with AQP9—was effective in fully correcting OTC activity and normalizing ureagenesis as assessed by 15NH4Cl stable‐isotope challenge. Conclusion: Our results identify a critical role for AQP9 in functional urea metabolism and establish the feasibility of in vitro modeling of OTCD with hiPSC‐Heps. By facilitating studies of OTCD genotype/phenotype correlation and drug screens, our model has potential for improving the therapy of OTCD.

25 June 2024 in Molecular Genetics and Metabolism
Verified
Journal Article
Open access
JKJasmine Koch
Jasmine Koch
MBMelissa H. Broeks
Melissa H. Broeks
MGMatthias Gautschi
Matthias Gautschi
JJJudith Jans
Judith Jans
ALAlexander Laemmle
Alexander Laemmle
The malate aspartate shuttle (MAS) plays a pivotal role in transporting cytosolic reducing equivalents - electrons - into the mitochondria for energy conversion at the electron transport chain (ETC) and in the process of oxidative phosphorylation. The MAS consists of two pairs of cytosolic and mitochondrial isoenzymes (malate dehydrogenases 1 and 2; and glutamate oxaloacetate transaminases 1 and 2) and two transporters (malate-2-oxoglutarate carrier and aspartate glutamate carrier (AGC), the latter of which has two tissue-dependent isoforms AGC1 and AGC2). While the inner mitochondrial membrane is impermeable to NADH, the MAS forms one of the main routes for mitochondrial electron uptake by promoting uptake of malate. Inherited bi-allelic pathogenic variants in five of the seven components of the MAS have been described hitherto and cause a wide spectrum of symptoms including early-onset epileptic encephalopathy. This review provides an overview of reported patients suffering from MAS deficiencies. In addition, we give an overview of diagnostic procedures and research performed on patient-derived cellular models and tissues. Current cellular models are briefly discussed and novel ways to achieve a better understanding of MAS deficiencies are highlighted.

19 October 2021 in Molecular Genetics and Metabolism Reports
Verified
Journal Article
Open access
ALAlexander Laemmle
Alexander Laemmle
ASAndrea Lisa Steck
Andrea Lisa Steck
ASAndré Schaller
André Schaller
SKSandra Kurth
Sandra Kurth
EHEveline Perret Hoigné
Eveline Perret Hoigné
MGMatthias Gautschi
Matthias Gautschi
Mitochondrial malate dehydrogenase (MDH2) deficiency (MDH2D) is an ultra-rare disease with only three patients described in literature to date. MDH2D leads to an interruption of the tricarboxylic acid (TCA) cycle and malate-aspartate shuttle (MAS) and results in severe early onset encephalopathy. Affected infants suffer from psychomotor delay, muscular hypotonia and frequent seizures. Laboratory findings are unspecific, including elevated lactate in blood and cerebrospinal fluid. Brain magnetic resonance imaging reveals delayed myelination and brain atrophy. Currently there is no curative therapy to treat this devastating disease.

12 March 2025 in Nature Communications
Verified
Journal Article
Open access
SGStefan Groeneweg
Stefan Groeneweg
FGFerdy S. van Geest
Ferdy S. van Geest
MMMariano Martín
Mariano Martín
MDMafalda Dias
Mafalda Dias
JFJonathan Frazer
Jonathan Frazer
WVW. Edward Visser
W. Edward Visser
Predicting and quantifying phenotypic consequences of genetic variants in rare disorders is a major challenge, particularly pertinent for ‘actionable’ genes such as thyroid hormone transporter MCT8 (encoded by the X-linked SLC16A2 gene), where loss-of-function (LoF) variants cause a rare neurodevelopmental and (treatable) metabolic disorder in males. The combination of deep phenotyping data with functional and computational tests and with outcomes in population cohorts, enabled us to: (i) identify the genetic aetiology of divergent clinical phenotypes of MCT8 deficiency with genotype-phenotype relationships present across survival and 24 out of 32 disease features; (ii) demonstrate a mild phenocopy in ~400,000 individuals with common genetic variants in MCT8; (iii) assess therapeutic effectiveness, which did not differ among LoF-categories; (iv) advance structural insights in normal and mutated MCT8 by delineating seven critical functional domains; (v) create a pathogenicity-severity MCT8 variant classifier that accurately predicted pathogenicity (AUC:0.91) and severity (AUC:0.86) for 8151 variants. Our information-dense mapping provides a generalizable approach to advance multiple dimensions of rare genetic disorders.

27 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
FLFelipe T. Lee-Montiel
Felipe T. Lee-Montiel
ALAlexander Laemmle
Alexander Laemmle
LDLaure Dumont
Laure Dumont
CLCaleb S. Lee
Caleb S. Lee
NHNathaniel Huebsch
Nathaniel Huebsch
KHKevin Healy
Kevin Healy
Microphysiological systems (MPSs) mimicking human organ function in vitro are an emerging alternative to conventional cell culture and animal models for drug development. Human induced pluripotent stem cells (hiPSCs) have the potential to capture the diversity of human genetics and provide an unlimited supply of cells. Combining hiPSCs with microfluidics technology in MPSs offers new perspectives for drug development. Here, the integration of a newly developed liver MPS with a cardiac MPS—both built with the same hiPSC line—to study drug-drug interaction (DDI) is reported. As a prominent example of clinically relevant DDI, the interaction of the arrhythmogenic gastroprokinetic cisapride with the fungicide ketoconazole was investigated. As seen in patients, metabolic conversion of cisapride to non-arrhythmogenic norcisapride in the liver MPS by the cytochrome P450 enzyme CYP3A4 was inhibited by ketoconazole, leading to arrhythmia in the cardiac MPS. These results establish functional integration of isogenic hiPSC-based liver and cardiac MPSs, which allows screening for DDI, and thus drug efficacy and toxicity, in the same genetic background.

27 May 2025 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
ARAdhuresa Ramosaj
Adhuresa Ramosaj
MBMariia Borsuk
Mariia Borsuk
JUJarl Underhaug
Jarl Underhaug
DMDéborah Mathis
Déborah Mathis
SMShirou Matsumoto
Shirou Matsumoto
ALAlexander Laemmle
Alexander Laemmle
Urea cycle disorders (UCDs) are inherited diseases causing recurrent life‐threatening metabolic decompensations due to impaired hepatic ammonia detoxification and decreased ureagenesis. Ornithine transcarbamylase (OTC) deficiency (OTCD) is X‐linked and the most common and often fatal UCD. In male hemizygous patients, disease severity primarily depends on the pathogenic sequence variant, while in heterozygous females, disease severity also depends on the X‐chromosomal inactivation (XCI) pattern. Females with unfavorable XCI predominantly expressing the mutant OTC protein may be severely affected. Here, we investigated a novel treatment strategy for OTCD since there is an unmet need for better therapies. In the first step, we performed a high throughput screening (HTS) using a diversity library with 10 000 chemical compounds to identify pharmacological chaperone (PC) candidates that stabilize purified wild‐type OTC. Stratification of our HTS results revealed five potential PCs, which were selected for further experimentation in cellular systems using primary human hepatocytes (PHHs) and human induced pluripotent stem cell (hiPSC)‐derived hepatocytes (hiPSC‐Heps) from healthy controls and OTCD patients. Two PCs—PC1 and PC4—increased OTC protein stability and activity in control hiPSC‐Heps, while PC4 in addition increased OTC activity in patient‐derived PHHs from a female OTCD patient with unfavorable XCI. Finally, PC1 and PC4 both significantly increased ureagenesis in patient‐derived PHHs. To conclude, we identified two PCs that stabilized wild‐type OTC and enhanced enzyme activity and ureagenesis. Our work suggests that PCs could provide a novel treatment strategy for OTCD specifically in females with unfavorable XCI.